TradeFlare's AI research teams analysed COGT on 4 market nights between August 5, 2026 and August 17, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 17, 2026 | BUY | $37.93 | — / — | -4.3% | -13.6% | The current market regime is neutral, and while COGT has some bullish sentiment, the technicals are neutral and the risk is high, preventing a buy recommendation. |
| August 13, 2026 | BUY | $38.98 | — / — | -5.4% | -10.4% | The stock is currently in a neutral market environment and the technicals are not strongly aligned for a buy. |
| August 12, 2026 | HOLD | $38.70 | — / — | -5.5% | -12.6% | Positive analyst sentiment driven by strong clinical data and FDA Priority Review. |
| August 5, 2026 | BUY | $42.84 | $48.30 / $35.70 | -7.8% | -18.2% | The setup suggests a short-to-medium term breakout play driven by technical momentum and upcoming catalysts. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.